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Abstract: Considered relevant during allergy responses, numerous observations have also identified
mast cells (MCs) as critical effectors during the progression and modulation of several neuroinflam-
matory conditions, including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). MC
granules contain a plethora of constituents, including growth factors, cytokines, chemokines, and
mitogen factors. The release of these bioactive substances from MCs occurs through distinct pathways
that are initiated by the activation of specific plasma membrane receptors/channels. Here, we focus
on hemichannels (HCs) formed by connexins (Cxs) and pannexins (Panxs) proteins, and we described
their contribution to MC degranulation in AD, ALS, and harmful stress conditions. Cx/Panx HCs are
also expressed by astrocytes and are likely involved in the release of critical toxic amounts of soluble
factors—such as glutamate, adenosine triphosphate (ATP), complement component 3 derivate C3a,
tumor necrosis factor (TNFα), apoliprotein E (ApoE), and certain miRNAs—known to play a role
in the pathogenesis of AD, ALS, and other neurodegenerative disorders. We propose that block-
ing HCs on MCs and glial cells offers a promising novel strategy for ameliorating the progression
of neurodegenerative diseases by reducing the release of cytokines and other pro-inflammatory
compounds.
Keywords: hemichannels; connexin; pannexin; mast cells; glial cells; inflammation; degranulation;
neurodegeneration; pro-inflammatory compounds; gap junction channels
1. Mast Cell Generalities
Mast cells (MCs) are resident immune cells from vascularized tissues that are closely
associated with blood vessels, glia, and neurons. In the central nervous system, MCs are
typically found within the dura mater, in the brain side of the blood–brain barrier (BBB),
choroid plexus, metencephalon, the thalamic–hypothalamic region, hippocampus, and
olfactory bulb [1–5].
In 1878, Paul Ehrlich described in his doctoral thesis aniline dye-positive granular
cells (“Mastzellen”), or well-fed cells found in the connective tissue [6]. Nowadays, it is
accepted that their main morphologic feature is numerous granules, which are not due
to hyper-nutrition but correspond to the storage of pre-formed inflammatory mediators
in proteoglycan and protease-enriched granules [7,8]. MCs originate from hematopoietic
bone marrow precursors in response to a stem cell factor, which is recognized by the tyro-
sine kinase receptor CD117 (or c-Kit receptor); promoting growth, survival, and migration.
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Precursors migrate into the blood to infiltrate peripheral tissues and differentiate at local mi-
croenvironments. The maturation dependence of local factors has led to recognizing MCs
heterogeneity in mammals, variable cell numbers, size, recognition of damage/pathogens,
activation response, sensitivity to inhibitors, granule numbers, and content along the same
body. In this context, two subtypes have been historically classified in rodents: connective
tissue MCs (found in peritoneal cavity, lungs, and skin) and mucosal MCs (gastrointestinal
tract and urinary bladder). Interestingly, MCs found in the brain share both phenotypes,
with staining characteristics similar to connective tissue MCs but the ultrastructural ap-
pearance and secretory content closer to the mucosal MCs [9]. Independent of the tissue
where they reside, rodent MCs share a characteristic expression of the stem cell factor (SCF)
receptor CD117, high-affinity serum Immunoglobulin E (IgE) receptor Fc epsilon RI (FcεRI),
and histamine inside the secretory granules [7].
MC granules present a diverse secretory content including growth factors, cytokines,
chemokines, and mitogen factors [10–12]. These mediators can be roughly classified in
pre-formed (stored in secretion granules, including amines, proteases, proteoglycans, lyso-
somal enzymes and cytokines such as tumor necrosis factor (TNFα) and SCF and de novo
synthesized mediators (including leukotrienes, prostaglandins, cytokines, chemokines,
nitric oxide (NO), and reactive oxygen species (ROS), presenting in both cases different
pathway for secretory release (Figure 1). De novo production of cytokines includes con-
stitutive secretion, while pre-formed release implies regulated exocytosis [13,14]. Since
MCs are secretory cells highly specialized into the massive release of all granular content
in a single event, this process is often referred to as degranulation response [15]. Although
in vivo compound exocytosis is the predominant form of regulated exocytosis during an
allergic response, the mode for degranulation is dictated by the stimulus [16]. Furthermore,
at a cellular level, MCs display a heterogeneous granule content, including association
with different vesicle fusion proteins [13,17–19] (Figure 1).
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Figure 1. General mechanisms of degranulation from activated MCs. (A) Mast cells (MCs) are resident immune cell
characterized by presenting numerous secretory granules in their cytoplasm in which they store pre-formed inflammatory
mediators, such as biogenic amines (e.g., histamine, serotonin), growth factors (e.g., nerve growth factor (NGF), vascular
endothelial growth factor (VEGF)), specific proteases (e.g., tryptase, chymase, carboxypeptidase A3), serglycin proteoglycan
(such as heparin and chondroitin sulfate), cytokines (e.g., IL-4 and tumor necrosis factor (TNFα)), and adenosine triphosphate
(ATP). These mediators are differentially packed in at least three different types (Types I, II, and III) of heterogenous secretory
granules along the cell. Upon activation, these pre-formed mediators are rapidly released to the extracellular medium in
a process called degranulation or regulated exocytosis, leading to immediate inflammatory reaction. Depending on the
stimulus, MCs activation can also trigger the de novo synthesis of inflammatory mediators in a process called constitutive
secretion, releasing molecules such as neuropeptides (e.g., substance P), growth factors (e.g., NGF, VEGF, platelet derived
growth factor (PDGF)), cytokines (e.g., IL-6, IL-1β, TNFα, SCF), and chemokines (e.g., Monocyte chemoattractant protein-1
(MCP-1)), modulating late phase inflammation responses. Both docking and fusion to the plasma membrane are dependent
on increased levels of the Ca2+ signal. The intracellular events triggered after MCs activation includes increasing membrane
permeability to Ca2+, ATP release, and purinergic receptor recruitment, which are key components for MCs degranulation.
(B) Different agents can induce MCs degranulation, including physical changes (e.g., temperature, vibrations, pressure,
stress, pH) and ligand–receptor interaction (e.g., antigen–Immunoglobulin E (IgE)–FcεRI, ATP–P2Y/X receptors, and Aβ
peptide–CD47). For the latter case, after intracellular signals are generated, connexins (Cxs) (potentially mediated by Cx43
and/or Cx32) and Panx1 HCs are eventually activated. HCs opening leads to massive ATP release, activating adjacent
purinergic receptors in an autocrine way. Purinergic P2X receptor activation allows Ca2+ influx and the direct recruitment
of more Panx1 HCs opening, leading to a vicious loop resulting in degranulation. (C) Different types of degranulation have
been reported for MCs, including full exocytosis, kiss-and-run exocytosis, piecemeal degranulation, multigranular, and
sequential compound exocytosis. However, compound exocytosis and piecemeal degranulation are the prevailing forms of
degranulation in human, mouse, and rat MCs. Although we have proposed HCs and purinergic receptors activation as key
components for MCs degranulation, contribution on constitutive secretion have not been evaluated. For more information
about inflammatory mediators, we recommend [10,20]; while for detailed reviews of regulated exocytosis mechanism,
we recommend revising [13,14,21–23]. Finally, the evidence of hemichannels (HCs) contribution on MCs degranulation is
indicated in [24,25].
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As a survey innate immune cells, MCs express a plethora of pathogen and damage-
associated molecular pattern receptors, which allow them to be activated by comple-
ment fragments (C3a, C4a, C5a), neuropeptides calcitonin gene-related peptide (CGRP),
corticotropin-releasing hormone (CRH), neurotensin, substance P, somatostatin) and phys-
ical conditions (cold, heat, pressure, stress, vibrations) [12]. Depending on the receptor
and the signal pathway recruited, MCs activation can induce the release of their gran-
ule content and/or de novo synthesis of inflammatory mediators. Activation through
compound 48/80 [26,27], neuropeptides [26,28–30], and IgE crosslinking reaction [31–37]
leads to both degranulation and constitutive secretion. Whereas activation without de-
granulation has been demonstrated upon exposure to lipopolysaccharides (LPS) [38] or
polyinosinic:polycytidylic acid (Poly(I:C)) viral-like particles [39–41]. Moreover, degranu-
lation without constitutive secretions has been demonstrated after complement peptides
activation [42–44].
2. Hemichannels Overview
Hemichannels (HCs) are non-selective plasma membrane channels permeable to
ions, and small molecules such as glucose, adenosine diphosphate (ADP), and adenosine
triphosphate (ATP), favoring cellular communication. In mammals, two families of pro-
teins form HCs: connexins (Cxs) and pannexins (Panxs) [45–47]. Despite the absence of
sharing homology in their amino acidic sequence (<16%), the oligomerization of these
transmembrane proteins leads to the formation of functional membrane channels. Some of
these channels allow cellular communication via the release of small molecules including
signaling molecules such as ATP, a reduced form of nicotinamide adenine dinucleotide
(NADH+), glutamate, and prostaglandin E2 [48–50] as well as the uptake of glucose from
extracellular media [51,52]. Additionally, molecules released via open HCs coordinate
paracrine and autocrine cell responses by activating other receptors in neighboring cells,
such as purinergic receptors. ATP and their hydrolysis products, ADP, AMP (adenosine
monophosphate), and adenosine, can trigger different responses through P2X, P2Y, and P1
receptors. Notably, these responses can also be propagated to cells lacking those receptors
via gap junction channels (GJCs) [53,54]. Gap junctional communication allows direct
cell-to-cell diffusional exchange of cytoplasmic ions and small molecules [47].
Cxs compose a family of highly conserved membrane proteins. To date, 21 genes
encoding human Cxs have been described and named by the suffix Cx followed by a
number that correspond to the approximate molecular mass. Each Cx presents four
transmembrane domains, where the amino and carboxyl ends are oriented toward the
cytoplasmic face of the cell membrane [55]. An increase of the Cx HC activity can be
promoted by mechanical stretch, metabolic stress, neurotransmitter receptor activation,
absence of extracellular divalent cations, and increase of cytoplasmic calcium ion (Ca2+). In
addition, Cxs also form GJCs between astrocytes, oligodendrocytes, and ependymal cells,
forming panglial networks [47].
On the other hand, the Panx family members are coded by three genes named PANX
1, 2, and 3 [56,57]. The Panx1 protein, the best-characterized family member, forms a
membrane channel that in its fully open stage corresponds to channel through which ATP
can be released to the extracellular medium [57,58]. The activity of this channel can be
enhanced by an increase of intracellular Ca2+ concentration, alkaline pH, high extracellular
potassium ion concentration, and extracellular ATP [49,57,59–62]. In contrast, the activity
of this channel is reduced via phosphorylation by protein kinase A (PKA) [63]. Upon
prolonged opening of this channel, a high amount of ATP (>1 mM) can be released, which
can promote neuronal cytotoxicity through the activation of P2X receptors. The latter
causes a sustained intracellular free Ca2+ concentration increase, membrane depolarization,
and decreased ATP production, leading to neuronal death [57,64–72]. However, high
extracellular ATP concentration can block the Panx1 HC [73] and, a persistent (more than
15 min) high extracellular ATP concentration causes the down-regulation of the channels,
reducing the number of channels available in the cell membrane [74]. In this context,
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Panx1 HCs directly modulate the initiation and propagation of Ca2+ waves, although the
channel per se is not permeable to Ca2+ [24]. For a complete guide on Cxs and Panxs HCs,
particularly in the brain, we recommend reading a recently published article [47].
3. Hemichannels on Mast Cell Immunological Function
Classic activation induced by antigen recognition through the IgE–FcεRI crosslinking
reaction is a well-known process that leads to rapid degranulation, lipid mediators release,
and de novo cytokines synthesis. For the degranulation response, which is induced within
seconds, soluble IgEs first bind with high affinity to the multichain immune recognition
class receptors FcεRIs. After antigen recognition crosslinking, the aggregation of the protein
complex induces the activation of the Src kinases Lyn and Fyn and the recruitment of the
ZAP70 tyrosine kinase family member Syk to the receptor complex and its subsequent
activation. Phospholipase C (PLCγ) is also activated and hydrolyzes phosphatidylinositol
4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
IP3 promotes the release of Ca2+ from intracellular stores and DAG activates protein kinase
C (PKC). Thanks to Ca2+ extrusion and chelation mechanisms, the depletion of intracel-
lular stores rapidly activates the endoplasmic reticulum Ca2+ sensor stromal interaction
molecule 1 (STIM1). The latter activates store-operated plasma membrane Ca2+ channel
calcium release-activated calcium channel protein 1 (ORAI1), which recruits an additional
plasma membrane Ca2+ permeable channel such as the transient receptor potential chan-
nels (TRPs) [75], increasing the membrane permeability to Ca2+ and slowly replenishing
intracellular stores. This signal is essential for MCs degranulation and chemotaxis [76].
Indeed, during intracellular Ca2+ measurement, ovalbumin (OVA) recognition induced
a fast-transient peak followed by a persistent increase of the Ca2+ signal mediated by
ionotropic purinergic P2X receptors activated by ATP released via Panx1 HCs [24].
As recently published, the opening of Panx1 HCs can also be induced after local sub-
membrane Ca2+ increase induced by nicotine acetylcholine receptor α7 (nAChR) activation
in chromaffin cells [77]. A similar mechanism might operate in MCs. since nicotine recep-
tors are expressed in murine MCs [78,79], although a contradictory modulation of degranu-
lation has been reported [80]. Murine MCs express Cx43, Cx32, and Panx1 [25,81] (Figure 1)
and form functional GJCs containing Cx43 with fibroblasts [82–84]. An important volume
of evidences have characterized cellular events for MCs activation during allergy and
neuroinflammatory conditions, but few studies have considered MCs HC-forming proteins
during the degranulation process. In this review, we will also include indirect evidences
for the potential contribution of MC HCs in different neuroinflammatory conditions.
4. Contribution of Mast Cells Hemichannels on Neuroinflammatory Conditions
4.1. Alzheimer’s Disease
The most prevalent form of dementia in the elderly worldwide is Alzheimer’s disease
(AD), which is characterized by an abnormal accumulation of amyloid β plaques and
neurofibrillary tangles, neuronal death, and synapse loss. So far, intense work over GJCs
and HCs cellular communication at early stages and during the progression in AD models
have been extensively revised [47,85–89]. First evidences started with the detection of high
Cx43 immunoreactivity at the amyloid plaque’s sites from biopsies of AD patients [90].
Similarly, in the double transgenic mice APPswe/PS1dE9, an enhanced immunoreactivity
of Cx43 and Cx30 was found at the amyloid plaques, which was mainly associated to
astrocytes; and interestingly, although microglia cells surround the amyloid plaques, Cx43
reactivity was not detected in these cells [91]. Long-term administration with a non-specific
HC inhibitor INI-0602, derived from glycyrrhetinic acid, did not altered the amyloid
deposition nor the activation marker expression (CD11b and glial fibrillary acidic protein
(GFAP)), but it inhibited the excessive glutamate release and reduced memory impairment
in AD mice models [92].
Using in vitro approaches, it has been possible to establish that after 24 h of amyloid
Aβ 25–35 incubation, cultured cortical microglia release an important amount of ATP and
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glutamate to the extracellular milieu through a Cx43- and Panx1 HC-dependent mecha-
nism [68]. In contrast, cultured astrocytes only after 72 h of amyloid Aβ 25–35 incubation
released glutamate and ATP but mainly via Cx43 HCs [68]. Treating neurons with con-
ditioned medium by astrocytes exposed to peptide amyloid Aβ 25–35 also induced the
activation of neuronal Panx1 and Cx36 HCs, promoting neuronal death through a mecha-
nism that involves the activation of neuronal P2X7 and N-methyl-D-aspartate (NMDA)
receptors [68]. However, in coronal brain slices, which present a more natural and complex
cellular micro environment, shorter incubation times (3 h) with amyloid peptide fragments
increased the HC activity of different cells. Particularly, increased HC activity has been
detected in pyramidal neurons, astrocytes, and microglia from hippocampus, and the
neuronal death depended exclusively on astrocytic Cx43 HCs activation [68], suggesting
the involvement of a paracrine cell–cell signaling via HCs.
Astrocytes located at amyloid plaque foci of hippocampal brain slices from APP-
swe/PS1dE9 mice, which also presented elevated Cx43 HC activity, unexpectedly show
unaltered gap junctional communication [93], contrasting with the reduced gap junctional
communication found in cultured astrocytes under inflammatory conditions [51,94]. In this
animal model, the astroglial genetic deletion of Cx43 prevented the dye uptake increase,
Ca2+ influx, ATP, and glutamate release, and it increased mitochondrial superoxide gener-
ation and the dystrophic neurites of hippocampal neurons [93]. Interestingly, long-term
treatment of APPswe/PS1dE9 mice with boldine, an HC but not a GJC inhibitor, prevented
the astrocyte and microglia activation, astrocytic Ca2+ signal alteration, and glutamate and
ATP release, and it alleviated the hippocampal neuronal suffering [95]. Together, these data
highlight the importance of astrocytic HCs activation during the progression of AD.
In brain samples from AD patients, activated tryptase-positive MCs have been found
in close association with amyloid plaque lesions [96]. In contrast, in skin and stomach
samples, phagocyted amyloid fragments inside MCs were also detected [97]. Indeed,
novel experiments have shown that rat peritoneal MCs recognize and phagocyte amyloid
fragments (fibrillar 1–40 and 1–42 peptides), inducing histamine secretion that depends on
the CD47/β1 integrin/Gi protein membrane complex [98,99]. In addition to the amyloid
beta fragments, the amyloid A protein precursor, called Serum Amyloid A (SAA), is also
elevated during inflammation in AD [100,101]. Notably, SAA also induces degranula-
tion, cytokine production (TNF-α and interleukin 1 (IL-1β)) and chemotaxis of human
MCs [102,103]. Granule contents, possibly through tryptase and heparin action, induce
the degradation of SAA, leading to the formation of protofibrillar intermediates [103],
suggesting an active role of MCs in the amyloid deposit formation. In addition, in bone
marrow-derived MCs, the acute exposure of amyloid β peptide fragment 25–35 induces
the degranulation of histamine via a mechanism that depends on Panx1 HCs [25]. The
amyloid activation increases the cell membrane current, dye uptake, and cytoplasmic
Ca2+ signal, which were reduced by Panx1 HC inhibitors or abrogated by the absent of
Panx1 in MCs from Panx1 null mice [25]. Interestingly, only uptake of 2-(4-amidinophenyl)-
1H-indole-6-carboxamidine (DAPI) and not ethidium bromide was detected, suggesting
that the selectivity of Panx1 HCs depends on the cell condition or the stimulus used to
increase the Panx1 HC activity. Moreover, in brain MCs, particularly from the prefrontal
cortex, amyloid peptide increases the permeability of both Cx43 and Panx1 channels to
ethidium bromide, contributing to degranulation evaluated as histamine release [25]. In
APPswe/PS1dE9 mice, brain MC population was drastically increased with respect to
control mice, particularly in the hippocampus and cortex [25]. Indeed, the infiltration
(and/or proliferation) of MCs in these areas was detected even before the onset of amyloid
plaque detection (at 3 months post-partum) [25]. In these animals, prefrontal cortex MCs
presented the “basal” uptake of ethidium bromide, which was drastically reduced by
Panx1 and Cx43 HC inhibitors, suggesting a simultaneous and reciprocal intervention in
the activation mechanism of these channels [25]. An important difference could occur when
comparing cells during the initial and chronic inflammatory phases of AD. It has been
proposed that during the onset of AD, particularly before amyloid plaque formation, MCs
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recognize low-soluble amyloid β fragments and migrate to the site where plaque aggrega-
tion will occur, in which they secrete inflammatory molecules and eventually compromise
the BBB [25]. After activation, MCs release protease gelatinases (metalloproteinases 2 and
9) and vascular endothelial growth factor (VEGF), leading to vascular leakage, leukocyte in-
filtration, and edema [104–106]. As the amyloid plaques matures, it is likely that microglia
become reactive, secrete pro-inflammatory cytokines, and release glutamate/ATP through
HCs, as it has been shown in vitro [68]. The latter could contribute to activate Cx43 HCs in
adjacent microglia and astrocytes during the progression of AD. This condition could be
worsen by other associated inflammatory conditions in which MCs activation leads to BBB
permeabilization, including cerebral ischemia [106–108], traumatic brain injury [109,110],
experimental autoimmune encephalomyelitis [111,112], and stress [113].
Targeting MCs activation has been explored, particularly using the MC stabilizer
masitinib (AB1010), which is a CD117 tyrosine kinase inhibitor developed by AB Bio-
science, S.A. (France). Treatment with masitinib prevents the differentiation, migration,
and activation of MCs [114]. Masitinib also targets platelet-derived growth factor receptors,
while it weakly affects Lyn, Fyn, and the focal adhesion kinase pathway [114]. Masitinib
totally prevents the amyloid-induced dye uptake in bone marrow-derived MCs and brain
MCs [25]. Importantly, the potential effect as HC blocker has been ruled out using HeLa
cells transfected with Cx43 or Panx1. In this system, the HC activity induced by exposure
to divalent cation-free solution or mechanical stress, respectively, was not affected by
masitinib [25].
A recent study evaluated the chronic effect of masitinib on APP/PS1dE9 mice pro-
gression [115]. Although masitinib treatment did not affect the amyloid plaque load nor
the IL-1β concentration in older animals treated daily for almost 2 months, it promoted
the recovery of spatial learning performance. Additionally, the decrease of synaptophysin
immunoreactivity detected in APP/PS1dE9 mice was completely recovered to normal
values after MC depletion or treatment with masitinib, suggesting an additional synaptic
protection [115]. Thanks to the AB Bioscience support, the anti-inflammatory effect of
masitinib is currently considered for the treatment of diverse diseases in which inflamma-
tion is either the cause or the consequence of the condition, including cancer, rheumatoid
arthritis, inflammatory bowel disease, asthma, multiple sclerosis, ALS, and AD [116–119].
A randomized placebo-controlled phase II trial study has revealed that 24 weeks of ma-
sitinib administration prevents the cognitive decline in mild to moderate advanced AD
patients [116].
4.2. Harmful Stress Conditions
Stress typically activates the hypothalamic–pituitary–adrenal axis, leading to the
production of catecholamines and glucocorticoids through the release of corticotropin-
releasing hormone (CRH). Interestingly, CRH affects the BBB permeability through MCs
activation [113,120]. In rats, acute non-traumatic immobilization stress during 30 min
promotes dura mater MCs degranulation and increased MC protease I content in the cere-
brospinal fluid, which is completely prevented by CRH antiserum [120]. This experimental
condition also increases diencephalon, cerebellum, and brainstem BBB extravasation of
Technetium gluceptate, which is prevented by the MC stabilizer cromolyn [113].
Through a CRH receptor type 1-mediated response, the cyclic adenosine monophos-
phate (cAMP) concentration of human MCs increases after 3 min of CRH exposure. In-
terestingly, the degranulation is not triggered, since neither histamine nor tryptase were
detected in the extracellular solution after 30 min of incubation. However, the activation of
CRH receptors promotes the proliferation and released of preformed TNF-α [121], which is
presumably stored in different granules from those containing histamine or tryptase. In ad-
dition, the de novo synthesis of IL-6, IL-8, and TNF-α cytokines was undetectable, but VEGF
was produced and released [122]. In addition, recognition of the released VEGF could serve
as chemotactic signal promoting microglia migration to the injury sites [123], suggesting a
potential cross-talk between MCs and microglia during stress responses [124–126].
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So far, the HCs contribution during stress-mediated MCs activation has not been
extensively studied. However, the HC activity of glial cells has been evaluated in both
acute and chronic restrain conditions [127]. In both cases, Panx1 HCs from hippocampal
microglia are activated, increasing the ethidium bromide uptake, and chronic restrain stress
promoted the strongest response [127]. Similarly, astrocytes and neurons presented high
HCs activity dependent on both Cx43 and Panx1 HCs [127]. Interestingly, during chronic
stress, the inhibition of NMDA/P2X7 receptors prevented the increase in both Panx1 and
Cx43 HCs activity, and HCs-mediated glutamate and ATP release [127].
In rats, stress induced with dexamethasone, a synthetic glucocorticoid, injected daily
during the last third of pregnancy induces activation of the nucleotide-binding oligomer-
ization domain (NOD)-, leucine-rich repeats (LRR)- and pyrin domain-containing protein
3 (NLRP3) inflammasome, expression of pro-inflammatory cytokines (IL-1β and TNF-α),
activation of purinergic receptors, and increase in Panx1 HC activity in hippocampal
oligodendrocytes of the offspring [128]. Interestingly, the inhibition of MCs or microglia
activation with masitinib and minocycline, respectively, prevents the increase HC activity
of oligodendrocytes, suggesting an upstream modulation of both HC types in these cells.
Although MCs seem to be activated before microglia, after 30 min of acute exposure to
dexamethasone, the HC activity, evaluated by ethidium bromide uptake, increases in
microglia, astrocytes, and oligodendrocytes [128].
4.3. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an untreatable disease characterized by the
degeneration of motoneurons. While the majority of patients have a sporadic form of the
disease (sALS), about 10% have familial ALS (fALS), which is associated with pathogenic
mutations (mut) in genes such as superoxide dismutase (SOD1), transactive response
DNA-binding protein 43 (TARDBP encoding TDP43), and C9ORF72 (which is characterized
by an intronic hexanucleotide expansion) [129–131]. Mutations in C9ORF72 and TARDBP
are also detected in patients with frontotemporal dementia (FTD), which is the second
most common cause of early dementia (<65 years) after AD, which is characterized by
progressive deficits in behavior, language, and executive functions, due to a progressive
neuronal atrophy and death in the frontal and temporal cortices [132]. Mutations in
C9ORF72 and TARDBP are also present in families that suffer simultaneously from both
diseases and thus exhibit motor dysfunction as well as cognitive impairments. Collectively,
familial and sporadic patients with ALS/FTD share many clinical and histopathological
features that suggest the involvement of a convergent, common mechanistic pathway.
Evidence obtained from co-cultures of brain cells as well as from animal models,
strongly indicate that astrocytes play a crucial role during the onset and progression of
ALS/FTD (reviewed in [133]). Thus, motoneuron damage and cell death is mediated
by astrocytes rather than intrinsic pathological processes of the motoneurons, and there-
fore, they are called non-cell autonomous mechanisms. Non-cell autonomous toxicity
to motoneurons has also been shown using conditioned media from human and mouse
astrocytes expressing ALS-linked mutations (SOD1, TARDBP, C9ORF72) or that lack identi-
fied causes of ALS (sALS) [134–142]. Despite considerable efforts, so far, the toxic factor
released by ALS astrocytes has not been identified, although a recent study by the Przed-
borski laboratory indicates that mutant SOD1 astrocytes release a soluble protein(s) or
fragment(s) between 5 and 30 kDa [143]. These and other studies rule out several usual
suspect molecules, such as glutamate, ATP, oxygen and nitrogen reactive species, TNFα,
and SOD1 [134,137,143]. Nonetheless, astrocytes release numerous additional small pro-
inflammatory molecules or bioactive substances, which can have pathological effects on
motoneurons (see Figure 2; [144,145]).
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amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). (B) Plasma membrane channels/receptors include
HCs (mainly Cx43 and Panx1), purinergic receptors (e.g., P2XR, P2YR), growth factor receptors (e.g., fibroblast growth factor
receptor (FGFR)) and ionic channels (e.g., VRAC, TREK-1; not shown). The influx of Ca2+ through HCs and ion channels—
along with the initiation of intracellular signaling cascades through purinergic and growth factor receptors—promotes
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concentra ion ([ 2 ]i), which is a process that leads to the extracellular release of many bioactive substances by exocytosis.
[Ca2+]i promotes the opening of Cx43 HCs and Panx HCs to directly release ATP into the extracellular environment. Cx43
HCs also release other small substances such as glutamate, NAD+, and glutathione. Extracellular Aβ also activates HCs. (C)
Vesicles, such as SLMVs (synaptic-like microvesicles), DCVs (dense-core vesicles), lysosomes and EVs (extracellular vesicles,
mainly microvesicles) contain diverse bioactive substances, including neurotransmitters, hormones and peptides, metabolic
substrates, growth factors, and inflammatory factors, among others. Particular membrane fusion molecules (e.g., VAMP2
and TiVAMP) regulate the release of the vesicles. While many membrane proteins and bioactive substances are identified,
little is known about the spatial and temporal aspects of vesicle release, including if membrane receptors/channels are
localized in sp cific microdomains to trigger localized intracellular signaling pathways, and if elevated, [Ca2+]i prom tes
the fusion of specific vesicle types with a memb ne tha is adjacent either o neuronal synapses or way fro he tripartite
synapse. Understanding the mechanisms that underlie the differential release of vesicles would potentially open therapeutic
avenues for constraining the secretion of critical toxic factors—such as glutamate, ATP, C3a, TNFα, apoliprotein E (ApoE),
and certain miRNAs identified to play a relevant role in the pathogenesis of Alzheimer´s disease and ALS/FTD—without
affecting the release of beneficial factors. Although less intensively studied, several of these toxic factors have been
implicated in other neurodegenerative diseases. Of interest, a recent report shows that mutant huntingtin (mHtt) associates
with Rab3a, which is a small GTPase localized on the membranes of DCVs, and it impairs brain-derived neurotrophic factor
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(BDNF) release from astrocytes. Another emerging topic is the potential role of connexons (mediated by Cx43 and Cx26) in
recruiting molecules such as RNA and DNA into microvesicles and exosomes and the subsequent intercellular transfer
of these vesicles. For simplicity, mHtt and connexons are not shown in the model. (D) The critical bioactive substances
glutamate and lactate can also be released by transmembrane transporters such as the cystiene/glutamate antiporter
(xCT), and monocarboxylate transporters (MCT1/4), respectively, independent of [Ca2+]i changes. The Na+-dependent
glutamate excitatory amino acid transporters (EAAT1/2) are relevant for the uptake of extracellular glutamate and make a
well-established contribution to excitotoxicity in ALS. For additional information on the release of bioactive substances and
on the role of HCs in astrocytes, see [47,144–147]; on the Aβ-mediated opening of HCs, see [68]; on mHtt and impaired
BDNF release from astrocytes, see [148]; and on connexons in the intercellular transfer of vesicles, see [149].
Accumulating data implicate a role for HCs in ALS: they contribute to the secretion of
various molecules, either directly through their pore, or indirectly by inducing vesicular re-
lease (Figure 2; [47,146]). In particular, Cx43 HCs are predominantly expressed in astrocytes
throughout the central nervous system (CNS) [150,151], and several studies report that
Cx43 (but not Cx30) protein expression is elevated in the spinal cord of symptomatic mutant
SOD1 rodent models [152–156]. Cx43 protein expression is also increased in postmortem
spinal cord and motor cortex tissues of sALS patients [155]. Moreover, the blockade of Cx43
HCs suppresses the disease progression (neuronal loss at the spinal cord and extended
survival) in mutant SOD1 animals treated with INI-0602 [92]. However, the Panx1 HCs
contribution should not be discarded, since INI-0602 is derived from glycyrrhetinic acid,
which is a molecule that not only inhibits Cxs but also blocks Panx1 HCs [157].
Astrocyte cultures harvested from the spinal cord of mutant SOD1 mice also display
increased Cx43 protein expression [155,158]; these cultured ALS astrocytes form functional
Cx43 HCs, as determined by ethidium bromide uptake in the presence of the specific Cx43
HC blocker Gap26 [155]. Notably, the Maragakis group has documented that relative
to control human astrocytes, Cx43 protein expression is augmented in human-induced
pluripotent stem cell (iPSC)-derived astrocytes from sALS (≈5-fold) and fALS patients who
harbor mutant SOD1 (≈3-fold) or C9ORF72 (≈6-fold) [155]. Given that such iPSC-derived
cultures are highly enriched in astrocytes and lack microglial cells [135], these results infer
that Cx43 HCs are intrinsically increased in ALS astrocytes. The application of the Cx43-
based channel blockers Gap26 (HCs and GJs) or Gap19 (HCs) to astrocyte–motoneuron
co-cultures significantly—but modestly—protects motoneurons from cell death [155]. To-
gether, these results point to a role for Cx43 HCs in the release of the toxic molecule(s) that
are present in ALS astrocyte-conditioned media and furthermore suggest that unknown
channels and/or receptors also contribute to the release mechanism: potential candidates
are Panx1 channels and purinergic P2X and P2Y receptors (see Figure 2). Primary astro-
cyte cultures of neonatal mutant SOD1 mice display higher amounts of Panx1 but not of
P2X7 [158]. Moreover, Panx1 transcripts are increased in the spinal cord of symptomatic
mutant SOD1 mice [156], and as discussed above, the treatment of mutant SOD1 animals
with the dual Cx and Panx1 HCs blocker INI-0602 was beneficial [92,157]. In addition
to their roles in ALS pathogenesis, Cx43 HCs and Panx1 HCs could also serve a critical
function in the progression of ALS by driving inflammatory responses (see below).
Although much less studied relative to ALS/FTD, studies in vitro have shown that
astrocytic non-cell autonomous effects are also evident in Alzheimer’s, Parkinson’s, and
Huntington’s disease [133]. For example, the release of glutamate and ATP by Alzheimer´s
disease astrocytes [68] and α-synuclein by Parkinson’s disease astrocytes [159] contributes
to neurodegeneration. For the role of glial Cx HCs and Panx HCs in Parkinson’s disease
and Huntington’s disease, we refer the reader to a recent review [47].
To our knowledge, direct evidence for MCs activation through an HC-dependent
mechanism has not been obtained in ALS. However, increased expression of Cx43 in spinal
cord of experimental models of ALS and in patients has been reported [152–156]. In the
ventral spinal cord of symptomatic mutant SOD1 mice, immunofluorescent staining also
reveals intense Cx43 labeling not only in GFAP-positive astrocytes but also in surrounding
GFAP-negative cells [155]. Indeed, Cx43 is expressed by MCs (see Figure 1) and activated
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microglia. Activation of resident and infiltrated MCs is of particular concern in ALS, as
these cells can significantly worsen the pro-inflammatory environment by unleashing a
cytokine storm (see Figure 1 and below). Here, we briefly discuss the presence and role of
MCs in ALS; we refer the reader to recent reviews for additional information [126,160–162].
In recent years, the Barbeito group has rigorously demonstrated a significant increase
in the number of MCs in a rat model of ALS, including in the extensor digitorum longus
(EDL) muscle, at the neuromuscular junction (NMJ), and in the sciatic nerve and its ventral
roots, starting at the time of disease onset [163–165]. The authors have also reported an
increased number of MCs in postmortem skeletal muscle of sALS patients [164]. In this
work, MCs were identified by their strong immunoreactivity and co-expression of tryptase,
chymase, and tyrosine kinase receptor c-kit, while additionally using Toluidine blue stain-
ing to identify a MC degranulating phenotype in the muscles of animals and patients with
ALS. Even though resident MCs are also observed in wild-type rats and healthy subjects,
these cells showed no evidence of degranulation. Together, these results suggest that MCs
infiltrate and/or proliferate in the skeletal muscle of both an ALS experimental model and
in patients with ALS, and that their degranulation contributes to disease progression.
Promising treatment of symptomatic mutant SOD1 rats with the tyrosine kinase in-
hibitor masitinib has been shown to decrease the number of MCs (and neutrophils) in
the EDL muscle, and it reduces the rate of NMJ denervation and motor deficits in rats
bearing the mutant SOD1 [163,166]. Clinical tests of masitinib in a phase III ALS trial also
demonstrate therapeutic benefits by slowing the deterioration of motor functions [119]. It
remains unclear how exactly masitinib targets skeletal muscle MCs in ALS and if this drug
prevents their activation and/or accumulation (through infiltration and/or local prolifera-
tion); studies with human cord-blood-derived MCs show that masitinib inhibits migration
and degranulation [114]. It is also not known whether MCs in the spinal cord play a role in
ALS and whether they are specifically targeted by masitinib, as immunofluorescence assays
fail to detect MCs in the spinal cord of symptomatic ALS rats [164] and mice [167]. This is a
surprising finding, because MCs, as with other bone marrow-derived immune cells, would
be expected to infiltrate the brain and spinal cord upon the disruption of the BBB. Sparse
accumulation of tryptase-positive MCs has been reported in postmortem spinal cord tissue
of patients, while no MCs have been detected in control subjects [168,169]. These latter
results support findings in healthy tissue that resident MCs are located in the dura mater of
the meninges around the spinal cord but not in the parenchyma [170–172]. It would be of
interest to understand why MCs accumulation is different in rodent versus human spinal
cord in ALS.
While masitinib likely delays disease progression in ALS patients by targeting MCs,
this inhibitor of the type-3 tyrosine kinase receptor also targets colony-stimulating factor
1 receptors (CSF-1Rs) that are expressed by microglial cells, pointing to a double action.
Similar neuroprotective effects in ALS were also observed in another study that used a
compound that targets MCs as well as microglia. Thus, chronic treatment of mutant SOD1
mice (from postnatal day 60 onwards) with diosodium chromoglycate (cromolyn)—an
FDA-approved compound that inhibits MC activation and degranulation and induces
anti-inflammatory microglia activation—decreases the degranulation of MCs in the anterior
tibialis muscle, reduces NMJ denervation, and extends the survival of ALS mice [173]. Cro-
molyn treatment also decreases the levels of some pro-inflammatory cytokines/chemokines,
including TNFα [162,173].
5. Conclusions and Future Directions
The outstanding plasticity of MCs is displayed upon a variety of stimuli, which can
lead to different activation responses: (1) release of pre-stored inflammatory mediators,
(2) release of de novo synthetized inflammatory mediators, or (3) both processes. These
responses impact the microenvironment of the tissue, since they cause vascular permeabi-
lization, leukocyte infiltration, and parenchymal cell interactions, among other outcomes.
Remarkably, these differences in activation response are evident among members of a
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heterogeneous MC population. Conversely, at least in two different populations of murine
MCs, immature bone marrow and mature brain MCs, Cx43, and Panx1 HCs opening seem
to mediate a key role during acute degranulation responses (including amyloid peptide
activation and crosslinking recognition). Despite the sharing progress so far generated,
important questions regarding MC biology still remain to be answered; here, we briefly
discuss several of them.
Particularly for the crosslinking IgE–FcεRI response, the intracellular pathways and
cargo release have been extensively studied during the past 50 years. However, mediators
and cellular events triggered after complement fragments, viral particles, or neuropeptides
treatment are still poorly defined. It would be of interest to evaluate whether Cx/Panx HCs
and purinergic signaling are also involved in MC activation in the absence of degranulation.
In addition, many of the responses of activated MCs have been evaluated on acute condi-
tions. However, they remain poorly studied during chronic conditions (e.g., AD and ALS).
In addition, it remains unknown whether under chronic conditions there is a persistent
release of granule content or a selective constitutive secretion. For the AD context, how
MCs interact with glia and neurons remains unknown. Other relevant questions are: Is
the increase in brain MCs number explained by MCs infiltration and/or proliferation? So
far, the involvement of Panx1 and Cx43 HCs has been evaluated in the APP/PS1 mice
model and mainly using in vitro assays. Whether the MC population response is similar in
non-transgenic models of AD such as Octodon degus, non-human primates, or dogs would
provide further proof of concept.
Similarly, plenty of literature support an important contribution of MCs during stress
conditions. However, the molecular identity of MC HCs present in chronic or acute stress
models has not been established, and the development of selective and potent blockers of
different HC types is of great interest not only to further understand their functional role,
but it would also be useful to reduce or prevent MC activation in different brain diseases
that evolve with the relevant neuroinflammatory response. In the same line of thought,
in vitro and in vivo models indicate a central role for astrocyte HCs during the onset of
ALS with an important role of degranulating MCs during the progression of this disease.
Thus, therapy designed to prevent or reduce MC activation in human ALS patients is
promising. In this context, how MCs become activated and communicate with astrocytes
still needs to be clarified.
Regarding other neurodegenerative conditions, including Huntington´s and Parkin-
son´s disease, the role of MCs HCs activation and their glial cell interaction are poorly
studied, and the current knowledge in AD and ALS can be useful to study these diseases.
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